title: Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis.
abstract: Tumor angiogenesis is the key process in tumor growth and metastasis, and transfers essential nutrients for solid tumor. Inhibition of tumor angiogenesis has been recognized as a more effective anti-cancer strategy for NSCLC and has acquired certain therapeutic effects. IDO has non-immune functions including regulating tumor angiogenesis and IDO dysregulation in cancer pathogenesis has been valued. Erianin is a natural product isolated from Dendrobium chrysotoxum Lindl. The antitumor activity of erianin in many kinds of cancers had been demonstrated in previous studies. In this study, we demonstrated that IDO could promote the attachment of 2LL cells, the ability of migration, invasion and VM formation, as well as the tubules forming ability of HUVECs. We also find that erianin suppressed expression and enzyme ability of IDO and erianin could inhibit IDO-induced metastasis and invasion ability of 2LL cells significantly. Erianin not only blocked IDO-induced tube formation of HUVECs, but also suppressed VM formation of 2LL-IDO cells. What's more, we examined that Erianin might play its role in angiogenesis through down-regulating phosphorylation of JAK2/STAT3, inhibiting its downstream target genes MMP-2/-9 and some inflammatory mediators (COX-2, HIF-1α and IL-6), which were all induced by IDO. All these results indicated that erianin had anti-angiogenesis ability and could inhibit the expresison of IDO to prevent and treat the malignant tumors.
authors.affiliation: Minhang Hospital, Fudan University, China.
authors.forename: Chang
authors.initials: C
authors.lastname: Su
authors.affiliation: School of Pharmacy, East China University of Science and Technology, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Zhang
authors.affiliation: School of Pharmacy, East China University of Science and Technology, China. Electronic address: liujian@ecust.edu.cn.
authors.forename: Jianwen
authors.initials: J
authors.lastname: Liu
authors.affiliation: Minhang Hospital, Fudan University, China. Electronic address: yioucao_doctor@126.com.
authors.forename: Yiou
authors.initials: Y
authors.lastname: Cao
mesh_terms: D000818:Animals; D001632:Bibenzyls / Q000494:pharmacology* / Q000627:therapeutic use*; D002138:Calibration; D018827:Carcinoma, Lewis Lung / Q000098:blood supply / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D045744:Cell Line, Tumor; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007249:Inflammation / Q000473:pathology; D051379:Mice; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D019800:Phenol; D015203:Reproducibility of Results; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D001632:Bibenzyls; C477638:Erianin; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D019800:Phenol
keywords: 3-dioxygenase (IDO); Angiogenesis; Erianin; Indoleamine 2; Lung cancer